148 related articles for article (PubMed ID: 17374740)
1. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.
Wagner-Ballon O; Pisani DF; Gastinne T; Tulliez M; Chaligné R; Lacout C; Auradé F; Villeval JL; Gonin P; Vainchenker W; Giraudier S
Blood; 2007 Jul; 110(1):345-53. PubMed ID: 17374740
[TBL] [Abstract][Full Text] [Related]
2. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis.
Kakumitsu H; Kamezaki K; Shimoda K; Karube K; Haro T; Numata A; Shide K; Matsuda T; Oshima K; Harada M
Leuk Res; 2005 Jul; 29(7):761-9. PubMed ID: 15927672
[TBL] [Abstract][Full Text] [Related]
3. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.
Yan XQ; Lacey D; Hill D; Chen Y; Fletcher F; Hawley RG; McNiece IK
Blood; 1996 Jul; 88(2):402-9. PubMed ID: 8695786
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.
Evrard S; Bluteau O; Tulliez M; Rameau P; Gonin P; Zetterberg E; Palmblad J; Bonnefoy A; Villeval JL; Vainchenker W; Giraudier S; Wagner-Ballon O
Blood; 2011 Jan; 117(1):246-9. PubMed ID: 20944070
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.
Chagraoui H; Tulliez M; Smayra T; Komura E; Giraudier S; Yun T; Lassau N; Vainchenker W; Wendling F
Blood; 2003 Apr; 101(8):2983-9. PubMed ID: 12506018
[TBL] [Abstract][Full Text] [Related]
6. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
An J; Sun Y; Fisher M; Rettig MB
Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
[TBL] [Abstract][Full Text] [Related]
7. [Effects of proteasome inhibitor bortezomib on NF-kappaB activity and ICAM-1 mRNA expression of K562 cells].
Lu SF; Lu H; Shen WY; Zhang JF; Liu P; Wang YR; Wang LX; Yang H; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1006-9. PubMed ID: 18928584
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
Gastinne T; Vigant F; Lavenu-Bombled C; Wagner-Ballon O; Tulliez M; Chagraoui H; Villeval JL; Lacout C; Perricaudet M; Vainchenker W; Benihoud K; Giraudier S
Exp Hematol; 2007 Jan; 35(1):64-74. PubMed ID: 17198875
[TBL] [Abstract][Full Text] [Related]
9. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.
Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; Raslova H; Villeval JL; Vainchenker W; Giraudier S
J Immunol; 2006 Jun; 176(11):6425-33. PubMed ID: 16709799
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
12. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
[TBL] [Abstract][Full Text] [Related]
14. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.
Chagraoui H; Komura E; Tulliez M; Giraudier S; Vainchenker W; Wendling F
Blood; 2002 Nov; 100(10):3495-503. PubMed ID: 12393681
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.
Russo SM; Tepper JE; Baldwin AS; Liu R; Adams J; Elliott P; Cusack JC
Int J Radiat Oncol Biol Phys; 2001 May; 50(1):183-93. PubMed ID: 11316563
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
18. PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.
Galimberti S; Canestraro M; Pacini S; Fazzi R; Orciuolo E; Trombi L; Mattii L; Battolla B; Capodanno A; Collecchi P; Veroni F; Simi P; Piaggi S; Casini A; Petrini M
Leuk Res; 2008 Jan; 32(1):103-12. PubMed ID: 17629554
[TBL] [Abstract][Full Text] [Related]
19. Myelofibrosis: experimental models and human studies.
Taskin AL; Cohen-Solal K; Le Couedic JP; Abina MA; Villeval JL; Debili N; Casadevall N; Vainchenker W; Wendling F
Stem Cells; 1998; 16 Suppl 2():155-64. PubMed ID: 11012187
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
